BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Daxas: Phase III/IV start

This quarter, Nycomed plans to start the 52-week, double-blind, placebo-controlled, international Phase III/IV REACT trial in about 2,000 patients to evaluate 500 µg Daxas in combination with a long-acting adrenergic receptor beta 2 ( ADRB2) agonist (LABA) and an inhaled corticosteroid...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >